Cost Effectiveness of Anticoagulation in Acute Coronary Syndromes

Author： Latour-Pérez Jaime   de-Miguel-Balsa Eva  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.4, 2012-04, pp. : 303-321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-effectiveness of ticagrelor in acute coronary syndromes

By Henriksson Martin   Janzon Magnus  

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Iss. 1, 2013-02 ,pp. : 9-18

Informa Healthcare

Access to resources Recommend Favorite

Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

By Bosanquet N.  

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1135-1152

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary Syndromes: A Canadian Hospital Perspective

By Balen R.M.  

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 533-542

Adis International

Access to resources Recommend Favorite

Cost-Effective Pharmacological Prevention of Acute Coronary Syndromes

By Monaco C.   Cianflone D.   Summaria F.   Maseri A.   Crea F.  

Pharmacological Research, Vol. 37, Iss. 6, 1998-06 ,pp. : 469-475

Academic Press

Access to resources Recommend Favorite

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

By Panattoni Laura   Brown Paul M.   >   Webster Mark   Gladding Patrick  

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 1067-1084

Adis International

Access to resources Recommend Favorite